Research News

A new scientific review has highlighted the growing potential of liquid biomarkers to transform the early detection, diagnosis, and treatment monitoring of colorectal cancer (CRC), offering a less invasive alternative to traditional screening methods such as colonoscopy.

Researchers from the University Hospital Bonn (UKB) and the University of Bonn have developed a new laboratory model that enables scientists to generate and study follicular regulatory T (Tfr) cells, a specialized group of immune cells responsible for controlling antibody responses. The breakthrough is expected to accelerate research into autoimmune diseases, vaccine responses, and immune regulation. The findings have been published in the journal Cellular & Molecular Immunology.

An international team of researchers has identified a previously unknown genetic cause of severe Crohn's disease in children, a breakthrough that could improve diagnosis and pave the way for more targeted treatments for inflammatory bowel disease (IBD). The findings were published in the journal Gastroenterology.

Researchers from Chiba University, Japan, have identified a promising strategy that could help prevent cancer from returning after treatment with KRAS-targeted drugs. The study reveals that a small population of cancer cells, known as drug-tolerant persister cells (DTPs), survives KRAS inhibitor therapy by rewiring its metabolism. By targeting these newly discovered survival mechanisms, scientists believe it may be possible to eliminate these residual cells and reduce the risk of relapse.

Researchers at Mass General Brigham have developed a promising blood test that could help physicians identify head and neck cancer patients at higher risk of disease recurrence and poorer survival outcomes, potentially enabling more personalized treatment strategies and follow-up care.

Researchers from Keio University School of Medicine in Japan have identified a previously unknown immune mechanism that may be responsible for sustaining the chronic autoimmune response seen in Sjögren’s disease. The discovery sheds new light on how the disease progresses and could open the door to targeted treatments that avoid the broad immune suppression associated with current therapies.

A groundbreaking European clinical trial has shown that using a common, harmless virus as a biomarker to guide immunosuppressive treatment after kidney transplantation is both safe and effective, paving the way for more personalized transplant care.